These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 39376549)

  • 1. Safety and Efficacy of Long-Term Tocilizumab in a Cohort of Patients with Giant Cell Arteritis: An Italian Monocentric Retrospective Study.
    Terribili R; Grazzini S; Conticini E; Falsetti P; Biasi G; Fabiani C; Cantarini L; Frediani B
    Biologics; 2024; 18():297-305. PubMed ID: 39376549
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Meteoritics Trial: efficacy of methotrexate after remission-induction with tocilizumab and glucocorticoids in giant cell arteritis-study protocol for a randomized, double-blind, placebo-controlled, parallel-group phase II study.
    Kreis L; Dejaco C; Schmidt WA; Németh R; Venhoff N; Schäfer VS
    Trials; 2024 Jan; 25(1):56. PubMed ID: 38225579
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Outcomes during and after long-term tocilizumab treatment in patients with giant cell arteritis.
    Matza MA; Dagincourt N; Mohan SV; Pavlov A; Han J; Stone JH; Unizony SH
    RMD Open; 2023 Apr; 9(2):. PubMed ID: 37024237
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Relapse Risk and Safety of Long-Term Tocilizumab Use Among Patients With Giant Cell Arteritis: A Single-Enterprise Cohort Study.
    Samec MJ; Rakholiya J; Langenfeld H; Crowson CS; Abril A; Wang B; Mertz L; Rodriguez-Pla A; Bansal P; Burke M; Jaquith J; Weyand C; Warrington KJ; Koster MJ
    J Rheumatol; 2023 Oct; 50(10):1310-1317. PubMed ID: 37321636
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term treatment with tocilizumab in giant cell arteritis: efficacy and safety in a monocentric cohort of patients.
    Regola F; Cerudelli E; Bosio G; Andreoli L; Tincani A; Franceschini F; Toniati P
    Rheumatol Adv Pract; 2020; 4(2):rkaa017. PubMed ID: 32685912
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical outcomes of patients with giant cell arteritis treated with tocilizumab in real-world clinical practice: decreased incidence of new visual manifestations.
    Unizony S; McCulley TJ; Spiera R; Pei J; Sidiropoulos PN; Best JH; Birchwood C; Pavlov A; Stone JH
    Arthritis Res Ther; 2021 Jan; 23(1):8. PubMed ID: 33407817
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tocilizumab in giant cell arteritis. Observational, open-label multicenter study of 134 patients in clinical practice.
    Calderón-Goercke M; Loricera J; Aldasoro V; Castañeda S; Villa I; Humbría A; Moriano C; Romero-Yuste S; Narváez J; Gómez-Arango C; Pérez-Pampín E; Melero R; Becerra-Fernández E; Revenga M; Álvarez-Rivas N; Galisteo C; Sivera F; Olivé-Marqués A; Álvarez Del Buergo M; Marena-Rojas L; Fernández-López C; Navarro F; Raya E; Galindez-Agirregoikoa E; Arca B; Solans-Laqué R; Conesa A; Hidalgo C; Vázquez C; Román-Ivorra JA; Lluch P; Manrique-Arija S; Vela P; De Miguel E; Torres-Martín C; Nieto JC; Ordas-Calvo C; Salgado-Pérez E; Luna-Gomez C; Toyos-Sáenz de Miera FJ; Fernández-Llanio N; García A; Larena C; Palmou-Fontana N; Calvo-Río V; Prieto-Peña D; González-Vela C; Corrales A; Varela-García M; Aurrecoechea E; Dos Santos R; García-Manzanares Á; Ortego N; Fernández S; Ortiz-Sanjuán F; Corteguera M; Hernández JL; González-Gay MÁ; Blanco R
    Semin Arthritis Rheum; 2019 Aug; 49(1):126-135. PubMed ID: 30655091
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Real-world Risk of Relapse of Giant Cell Arteritis Treated With Tocilizumab: A Retrospective Analysis of 43 Patients.
    Clément J; Duffau P; Constans J; Schaeverbeke T; Viallard JF; Barcat D; Vernhes JP; Sailler L; Bonnet F
    J Rheumatol; 2021 Sep; 48(9):1435-1441. PubMed ID: 33589561
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Taper versus discontinuation of tocilizumab in patients with giant cell arteritis: Real-world experience from a tertiary center.
    Nielsen MK; Nielsen AW; Donskov AO; Hansen IT; Nielsen BD; Mørk C; Hauge EM; Keller KK
    Semin Arthritis Rheum; 2024 Oct; 68():152508. PubMed ID: 38981187
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Faster steroid-free remission with tocilizumab compared to methotrexate in giant cell arteritis: a real-life experience in two reference centres.
    Quartuccio L; Treppo E; De Martino M; Pillon M; Perniola S; Bruno D; Isola M; Gremese E
    Intern Emerg Med; 2024 Aug; ():. PubMed ID: 39093541
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Optimisation of tocilizumab therapy in giant cell arteritis. A multicentre real-life study of 471 patients.
    Calderón-Goercke M; Loricera J; Moriano C; Castañeda S; Narváez J; Aldasoro V; Maiz O; Melero R; Villa JI; Vela P; Romero-Yuste S; Callejas JL; de Miguel E; Galíndez-Agirregoikoa E; Sivera F; Fernández-López JC; Galisteo C; Ferraz-Amaro I; Sanchéz-Martín J; Sánchez-Bilbao L; González-Gay MA; Hernández JL; Blanco R;
    Clin Exp Rheumatol; 2023 Apr; 41(4):829-836. PubMed ID: 36377586
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment failure in giant cell arteritis.
    Unizony SH; Bao M; Han J; Luder Y; Pavlov A; Stone JH
    Ann Rheum Dis; 2021 Nov; 80(11):1467-1474. PubMed ID: 34049857
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tocilizumab for the treatment of large-vessel vasculitis (giant cell arteritis, Takayasu arteritis) and polymyalgia rheumatica.
    Unizony S; Arias-Urdaneta L; Miloslavsky E; Arvikar S; Khosroshahi A; Keroack B; Stone JR; Stone JH
    Arthritis Care Res (Hoboken); 2012 Nov; 64(11):1720-9. PubMed ID: 22674883
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intravenous tocilizumab for the treatment of giant cell arteritis: a phase Ib dose-ranging pharmacokinetic bridging study.
    Schmitt C; Brockwell L; Giraudon M; Zucchetto M; Christ L; Bannert B; Daikeler T; Villiger PM
    Arthritis Res Ther; 2022 Jun; 24(1):133. PubMed ID: 35659282
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Health-related quality of life in patients with giant cell arteritis treated with tocilizumab in a phase 3 randomised controlled trial.
    Strand V; Dimonaco S; Tuckwell K; Klearman M; Collinson N; Stone JH
    Arthritis Res Ther; 2019 Feb; 21(1):64. PubMed ID: 30786937
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tocilizumab in giant cell arteritis: Multicenter open-label study of 22 patients.
    Loricera J; Blanco R; Hernández JL; Castañeda S; Mera A; Pérez-Pampín E; Peiró E; Humbría A; Calvo-Alén J; Aurrecoechea E; Narváez J; Sánchez-Andrade A; Vela P; Díez E; Mata C; Lluch P; Moll C; Hernández Í; Calvo-Río V; Ortiz-Sanjuán F; González-Vela C; Pina T; González-Gay MÁ
    Semin Arthritis Rheum; 2015 Jun; 44(6):717-23. PubMed ID: 25697557
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tocilizumab in Giant Cell Arteritis: A Real-Life Retrospective Study.
    Vitiello G; Orsi Battaglini C; Carli G; Radice A; Matucci A; Vultaggio A; Olianti C; Parronchi P; Maggi E; Cammelli D
    Angiology; 2018 Oct; 69(9):763-769. PubMed ID: 29343075
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tocilizumab for giant cell arteritis.
    Antonio AA; Santos RN; Abariga SA
    Cochrane Database Syst Rev; 2022 May; 5(5):CD013484. PubMed ID: 35560150
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tocilizumab for giant cell arteritis.
    Antonio AA; Santos RN; Abariga SA
    Cochrane Database Syst Rev; 2021 Aug; 8(8):CD013484. PubMed ID: 34420204
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tocilizumab in Giant Cell Arteritis: A Multicenter Retrospective Study of 34 Patients.
    Régent A; Redeker S; Deroux A; Kieffer P; Ly KH; Dougados M; Liozon E; Larroche C; Guillevin L; Bouillet L; Espitia O; Costedoat-Chalumeau N; Soubrier M; Brihaye B; Lifermann F; Lefevre G; Puéchal X; Mouthon L; Toussirot E;
    J Rheumatol; 2016 Aug; 43(8):1547-52. PubMed ID: 27182063
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.